Brief: Ocumension Therapeutics Says Phase III Clinical Trial Of Ot-1001 (Zerviate) Approved In China
22/09/2020 24:59
Sept 22 (Reuters) - Ocumension Therapeutics 1477.HK :
* PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) APPROVED IN
CHINA
Source text for Eikon: ID:nHKS24t43w
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application